Abstract
Objective: To compare efficacy with percentage reduction in lipid profile of Rosuvastatin versus Simvastatin along with tolerability in
patients of coronary artery disease.
Study Design: A randomized clinical trial
Setting: Cardiology Department of Medical Testing and Research Organization Islamabad from 1st October till 1st December 2016.
Methodology: A total of one hundred six patients with coronary artery disease were randomized into two equal groups to give
Rosuvastatin 5mg to group I and Simvastatin 20mg to group II for eight weeks. As per guidelines of treatment of dyslipidemia the
primary outcome was to lower LDLC< 100mg/dl. Secondary treatment outcomes were reduction of Total Cholesterol, elevation in
HDL-Cholesterol and tolerability of both drugs.
Results: Rosuvastatin Group consisted of 62.3% males and 37.7% females while Simvastatin Group had 56.6% males and 43.4%
females. Patients aged 55.20 ± 7.16 years in group I and 56.83 ± 6.30 years in group II. Primary treatment outcome was attained in
patients of Rosuvastatin Group 75.5% as paralleled to Simvastatin 47.2%. Reduction in LDL-C from initial and terminal analyses showed
significant results (Rosuvastatin 44.2% whereas Simvastatin group 39.4%). Data produced by Rosuvastatin group revealed clinically
significant decrease in total Cholesterol 37.6% as compared to Simvastatin group 28.2% while more rise in HDL-C was determined in
Rosuvastatin group 16.9% than Simvastatin group 7.1 %. No serious adverse effects were found in both treatments groups.
Conclusion: Rosuvastatin is more potent lipid modifying agent than Simvastatin and it has similarity to Simvastatin in tolerability.
Anjum Ilahi, Adnan Saleem Khan, Sadia Zainab, Mansur Ilahi. (2019) Comparison of lipid profile improvements with low dose of rosuvastatin and simvastatin as lipid lowering drugs in high risk patients: A randomized clinical trial, Isra Medical Journal, Volume 11, Issue 3.
-
Views
586 -
Downloads
97
